Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.00665706 | 0.325018 | 0.311691 |
Schistosoma mansoni | hypothetical protein | 0.0190724 | 1 | 1 |
Loa Loa (eye worm) | CYP4Cod1 | 0.00103496 | 0.0193614 | 0.0193614 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0190724 | 1 | 1 |
Trypanosoma brucei | hypothetical protein, conserved | 0.00665706 | 0.325018 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.00103496 | 0.0193614 | 0.0193614 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.00665706 | 0.325018 | 1 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0190724 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.00665706 | 0.325018 | 0.325018 |
Onchocerca volvulus | 0.0190724 | 1 | 1 | |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0190724 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0190724 | 1 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.00665706 | 0.325018 | 1 |
Trypanosoma brucei | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.00665706 | 0.325018 | 1 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.00665706 | 0.325018 | 1 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0190724 | 1 | 0.5 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.00665706 | 0.325018 | 0.311691 |
Schistosoma mansoni | hypothetical protein | 0.0190724 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.00665706 | 0.325018 | 1 |
Brugia malayi | brahma associated protein 60 kDa | 0.0190724 | 1 | 1 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0190724 | 1 | 1 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0190724 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.00665706 | 0.325018 | 1 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.00665706 | 0.325018 | 1 |
Brugia malayi | YY1-associated factor 2 | 0.00665706 | 0.325018 | 0.311691 |
Leishmania major | hypothetical protein, conserved | 0.00665706 | 0.325018 | 1 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0190724 | 1 | 1 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0190724 | 1 | 1 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0190724 | 1 | 1 |
Loa Loa (eye worm) | brahma associated protein | 0.0190724 | 1 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.00103496 | 0.0193614 | 0.0193614 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.00665706 | 0.325018 | 1 |
Trypanosoma brucei | mitochondrial RNA binding complex 1 subunit | 0.00665706 | 0.325018 | 1 |
Chlamydia trachomatis | SWIB complex protein | 0.0190724 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.00665706 | 0.325018 | 0.325018 |
Loa Loa (eye worm) | hypothetical protein | 0.00665706 | 0.325018 | 0.325018 |
Trypanosoma brucei | hypothetical protein, conserved | 0.00665706 | 0.325018 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.00665706 | 0.325018 | 0.325018 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.00665706 | 0.325018 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.00665706 | 0.325018 | 0.325018 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.00665706 | 0.325018 | 1 |
Schistosoma mansoni | brg-1 associated factor | 0.0190724 | 1 | 1 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0190724 | 1 | 1 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0190724 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.00665706 | 0.325018 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0190724 | 1 | 1 |
Brugia malayi | brahma associated protein 60 kDa | 0.0190724 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.00665706 | 0.325018 | 1 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0190724 | 1 | 0.5 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.00103496 | 0.0193614 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.00665706 | 0.325018 | 1 |
Leishmania major | hypothetical protein, conserved | 0.00665706 | 0.325018 | 1 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0190724 | 1 | 1 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.00665706 | 0.325018 | 0.311691 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.00665706 | 0.325018 | 1 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.00665706 | 0.325018 | 0.311691 |
Plasmodium vivax | hypothetical protein, conserved | 0.0190724 | 1 | 0.5 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0190724 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0.81 ug ml-1 | Antimicrobial activity against Plasmodium falciparum D6 by microdilution method | ChEMBL. | 21282058 |
IC50 (functional) | = 2.07 ug ml-1 | Antimicrobial activity against Plasmodium falciparum TM91C235 by microdilution method | ChEMBL. | 21282058 |
IC50 (functional) | = 2.68 ug ml-1 | Antimicrobial activity against Plasmodium falciparum W2 by microdilution method | ChEMBL. | 21282058 |
MED (functional) | > 320 mg/kg/day | Antiplasmodial activity against Plasmodium berghei sporozoites infected in orally dosed mouse administered for three consecutive days one day before infection | ChEMBL. | 21282058 |
MTD (ADMET) | >= 320 mg/kg/day | Toxicity in Plasmodium berghei sporozoites infected orally dosed mouse administered for three consecutive days one day before infection | ChEMBL. | 21282058 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 21282058 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.